Immunetech
Executive Summary
Files IND for clinical testing of TCMP-80, a T-cell modulatory peptide, in the treatment of multiple sclerosis. Trials of the synthetic peptide are slated to begin this spring in San Diego. Frim has an NDA pending for a subcutaneous anti-allergy compound, pentigetide, with submissions planned for nasal and ophthalmic formulations later this year.